4
Indication details
- Control Arm
- Single arm
- Therapeutic Indication
- Adult patients with metastatic Merkel cell carcinoma (MCC)
- Tumour Type
-
Skin Cancers
- Tumour Sub-type
- Merkel cell carcinoma
- Tumour Stage
- Metastatic
- Trial Name
- JAVELIN Merkel 200 (Part A - pretreated patients)
- NCT Number
- NCT02155647
- Trial Phase
- Phase II
Approval details
- FDA Approval
- FDA approval March 2017
- EMA Approval
- EMA (CHMP) July 2017 EC decision September 2017
Primary Outcome(s)
- Primary Outcome(s)
- ORR/DoR
- Evaluated Outcome
- ORR
- Form(s)
- Form 3
Outcome Data
- ORR
- 33.0%
- DoR
- 40.5 months 5-year survival: 26%*
Adjustments
- QoL Comment
-
QoL was not a prespecified endpoint
Final Score (after adjustments)
- Preliminary non-curative score
-
3
- QoL adjustment
- 1+ (Upgrade based on expanded access and real-world experience)
- Final non-curative score
-
4
- Comment
-
*Prior to the use of immunotherapies targeting PD-1 or its major ligand, PD-L1, patients with advanced Merkel cell carcinoma had an expected 5-year OS of 14%-27%.
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 248
- Scorecard version
- 1
- Issue date
- 26.03.2021
- Last update
- 04.12.2023
Legend
Information about symbols, abbrevations and color codes
Red = negative
Green = positive
Grey = neutral
?
Grey + ? = neutral with pending data
- DFS
- Disease-Free Survival
- DoR
- Duration of Response
- EFS
- Event-Free Survival
- HR
- Hazard Ratio
- NEB
- No evaluable benefit
- NI
- Non-inferiority Study
- ORR
- Overall Response Rate
- OS
- Overall Surival
- pCR
- Pathological Complete Response/Remission
- PFS
- Progression-Free Survival
- QoL
- Quality of Life
- RFS
- Relapse-Free Survival
- RR
- Response Rate
QoL adjustments
Other adjustments*
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
QoL adjustments
Red = negative / deterioration
Green = positive / improvement
Other adjustments*
Red = negative / deterioration
Green = positive / improvement
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
* Other adjustments include:
- Long-term plateau in the survival curve
- Long-term plateau in the PFS curve
- Early stopping or crossover
- Only improved PFS mature data shows no OS advantage and no improved Qol.